復宏漢霖:首個在一線肺癌領域做口頭報吿的國產抗PD-1單抗數據公佈
格隆匯6月6日丨復宏漢霖(2696.HK)今日宣佈,公司首個創新型單抗H藥漢斯狀®(斯魯利單抗)針對一線廣泛期小細胞肺癌(ES-SCLC)的國際多中心III期臨牀研究(ASTRUM-005)在2022年美國臨牀腫瘤學會(ASCO)年會由主要研究者吉林省腫瘤醫院程穎教授進行了口頭報吿。這也是中國自主研發的抗PD-1單抗首次在一線肺癌領域以口頭報吿形式在ASCO年會進行彙報,充分展現出中國醫藥企業在創新生物藥領先的研發能力和國際臨牀運營實力。試驗結果表明,斯魯利單抗聯合卡鉑-依託泊苷能明顯改善一線ES-SCLC患者的OS,且其安全性與之前的研究結果一致。斯魯利單抗有望成為全球首個一線治療ES-SCLC的抗PD-1單抗產品,為此類患者提供一種新的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.